Skip to main content
TipRanks
Go Ultimate75% OFF

Roche Holding AG (RHOA) Q2 2026 Earnings Report

71 Followers

DE:RHOA Q2 2026 EPS Results

Actual EPS
EUR 11.77
Consensus EPS
EUR 11.20
Beat/Miss
Beat by +EUR 0.56
One Year Ago EPS
EUR 12.02

DE:RHOA Q2 2026 Revenue Results

Actual Revenue
EUR 32.93B
Expected Revenue
EUR 16.87B
Beat/Miss
Beat by +EUR 16.06B
YoY Revenue Growth
-1.87%

Earnings Announcement Details

Quarter
Q2 2026
Date
07/23/2026
Time
Before Open
Conference Call
Thursday, July 23, 2026
DE:RHOA Upcoming Earnings

Roche Holding AG's next earnings date is estimated for January 28, 2027, based on past reporting schedules.

Q2 2026 Earnings Call Audio

DE:RHOA Q2 2026 Earnings Call
0:00 / 0:00

Q2 2026 Earnings Slide Deck

Q2 2026 Earnings Call Summary

Q2 2026
Earnings Call Date:Jul 23, 2026|% Change Since:22.19%|
Earnings Call Sentiment|Positive

The call conveyed strong operational and financial momentum (core operating profit +10%, margin expansion, robust cash flow) combined with substantial pipeline and regulatory momentum (5 FDA priority reviews, 80% Phase III success YTD, multiple product launches/CE marks, and strategic diagnostics M&A). Headwinds were acknowledged and specific: China diagnostics pricing reform, weaker respiratory season, currency translation effects, net debt increase from dividends/timing, competitive pressures (biosimilars) and some impairments. Overall, the positive operational and pipeline developments materially outweigh the challenges, and management maintained confident guidance (mid-single-digit sales growth, high-single-digit core EPS growth) while flagging manageable near-term risks.

Company Guidance

Roche stuck to its 2026 guidance: mid‑single‑digit sales growth (group H1 at 6%), high‑single‑digit core EPS growth (core EPS +9% in H1) and a further dividend increase in CHF; management reiterated an expected LOE headwind of roughly CHF 600m for 2026. H1 showed core operating profit +10% (core operating margin +1.7pp), pharma +6% and diagnostics +3% (diagnostics +6% ex‑China; China -15%), with a flu‑season impact of >CHF200m (~1%). Cash metrics were strong: operating free cash flow +21% (+2% in CHF), free cash flow +58% (+26% in CHF), while net debt rose CHF 5.9bn (gross debt ~CHF31.8bn). Diagnostics reaffirmed a 2026 ambition to keep margins broadly stable (~14.4% FY25 level) while targeting mid‑single‑digit sales growth and mid‑ to high‑single‑digit growth in 2027; management also flagged currency headwinds (~‑4 to ‑6 ppts on FY sales/OP/EPS) and a core tax rate of 17.5% in H1, expected to be around 20% for the full year, and said other revenue is expected to rise from ~3% to ~5% of sales by the end of the decade.

  • Strong Profitability ExpansionCore operating profit increased +10% (CER) and core operating margin expanded by +1.7 percentage points; core EPS grew +9% — demonstrating margin expansion ahead of sales growth.
  • Solid Sales Growth at Constant Exchange RatesGroup sales growth reported at +6% (pharma +6% CER; diagnostics +3% CER); pharma sales reached CHF 23.6 billion (6% CER, 8% in USD, -1% in CHF).
  • Robust Cash Flow GenerationOperating free cash flow increased +21% (plus +2% in CHF) and free cash flow rose +58% (timing effects noted); strong cash generation underpins dividend increase and reinvestment.
  • Significant Pipeline and Regulatory MomentumFive U.S. FDA priority reviews granted year-to-date; Phase III success rate reported at 80% YTD with two positive Phase III readouts in the quarter; multiple filings and near-term readouts expected (several Phase III events and NMEs planned).
  • Notable Clinical Wins — Oncology and HematologyPositive Phase III KRASCENDO-1 (divarasib) showed superiority vs approved G12C inhibitors with PFS and OS improvements (OS reached statistical significance at interim); hematology franchise grew +14% CER driven by Hemlibra and Polivy uptake.
  • Diagnostics Product and M&A ProgressAXELIOS 1 sequencing solution launched (June 29) leveraging SBX chemistry; CE marks/launches for Elecsys pTau217 (Alzheimer’s) and Elecsys IGRA TB test; completed strategic acquisition of PathAI to augment digital pathology capabilities.
  • Obesity/CVRM Portfolio AdvancementPositive Phase II data for petrelintide (placebo-like tolerability) and enicepatide (48% of patients achieved >20% weight loss; 26% achieved >30% at highest dose); petrelintide Phase III decision taken and Phase III starts planned H2.
  • Lower-than-anticipated LOE ImpactLoss-of-exclusivity (LOE) impact in H1 was CHF 244 million and the company now expects LOE impact of roughly CHF 600 million for 2026 — a smaller headwind than earlier guidance.

DE:RHOA Earnings History

DE:RHOA earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Jan 28, 20272026 (Q4)10.52-9.08――
Jul 23, 20262026 (Q2)11.2011.7712.02-2.08% (-0.25)
Jan 29, 20262025 (Q4)9.249.089.3-2.28% (-0.21)
Jul 24, 20252025 (Q2)11.6812.0211.18.31% (+0.92)
Jan 30, 20252024 (Q4)8.819.309.191.18% (+0.11)
Jul 25, 20242024 (Q2)10.1611.1037.69-70.56% (-26.59)
Feb 01, 20242023 (Q4)9.089.198.972.42% (+0.22)
Jul 27, 20232023 (Q2)11.0137.6912.76195.46% (+24.93)
Feb 02, 20232022 (Q4)9.378.9710.03-10.59% (-1.06)
Jul 21, 20222022 (Q2)9.9212.7611.4511.36% (+1.30)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed